Patents by Inventor Chen-Yong Lin
Chen-Yong Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11752215Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: GrantFiled: March 12, 2021Date of Patent: September 12, 2023Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITYInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
-
Publication number: 20210299270Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: March 12, 2021Publication date: September 30, 2021Applicants: Rutgers, The State University of New Jersey, Georgetown UniversityInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
-
Publication number: 20210177985Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: February 24, 2021Publication date: June 17, 2021Applicants: Rutgers, The State University of New Jersey, Georgetown UniversityInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Publication number: 20190358340Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: August 8, 2019Publication date: November 28, 2019Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Patent number: 10376597Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: GrantFiled: December 1, 2017Date of Patent: August 13, 2019Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITYInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Publication number: 20190151464Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: March 17, 2017Publication date: May 23, 2019Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Zoltan Szekely
-
Patent number: 10175238Abstract: The present invention relates to methods of determining the presence or absence of abnormal lymphoid cells or abnormal myeloid cells in a cell sample, with the methods comprising subjecting the cell sample to conditions that will activate any inactive matriptase present in the cell sample and measuring the levels of activated matriptase in the cell sample. Once measured, these levels can then be compared to control levels of active matriptase to determine if the cell sample has elevated levels of activated matriptase over control levels of active matriptase. An elevation in the levels of activated matriptase in the cell sample is indicative that the cell sample contains abnormal lymphoid cells or abnormal myeloid cells.Type: GrantFiled: May 13, 2015Date of Patent: January 8, 2019Assignee: Georgetown UniversityInventors: Chen-Yong Lin, Michael D. Johnson, Feng-Pai Chou
-
Publication number: 20180177889Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: December 1, 2017Publication date: June 28, 2018Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Patent number: 9849192Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E(MMAE) and monomethyl auristatin F(MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: GrantFiled: March 18, 2016Date of Patent: December 26, 2017Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITYInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Patent number: 9682094Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: GrantFiled: August 26, 2015Date of Patent: June 20, 2017Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITYInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Patent number: 9549993Abstract: Disclosed are antibody drug conjugates (ADC) that include highly potent toxic agents with specific antibodies to target tumors. Also disclosed are related antibodies, polypeptides, nucleic acids, host cells, compositions, and uses.Type: GrantFiled: October 2, 2013Date of Patent: January 24, 2017Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, GEORGETOWN UNIVERSITYInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Michael Johnson
-
Publication number: 20160263244Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: March 18, 2016Publication date: September 15, 2016Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Publication number: 20160015728Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: August 26, 2015Publication date: January 21, 2016Inventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Publication number: 20150338409Abstract: The present invention relates to methods of determining the presence or absence of abnormal lymphoid cells or abnormal myeloid cells in a cell sample, with the methods comprising subjecting the cell sample to conditions that will activate any inactive matriptase present in the cell sample and measuring the levels of activated matriptase in the cell sample. Once measured, these levels can then be compared to control levels of active matriptase to determine if the cell sample has elevated levels of activated matriptase over control levels of active matriptase. An elevation in the levels of activated matriptase in the cell sample is indicative that the cell sample contains abnormal lymphoid cells or abnormal myeloid cells.Type: ApplicationFiled: May 13, 2015Publication date: November 26, 2015Inventors: Chen-Yong Lin, Michael D. Johnson, Feng-Pai Chou
-
Publication number: 20150250895Abstract: Disclosed are antibody drug conjugates (ADC) that include highly potent toxic agents with specific antibodies to target tumors. Also disclosed are related antibodies, polypeptides, nucleic acids, host cells, compositions, and uses.Type: ApplicationFiled: October 2, 2013Publication date: September 10, 2015Applicant: Georgetown UniversityInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin, Michael Johnson
-
Publication number: 20120294800Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: November 18, 2010Publication date: November 22, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Patent number: 7960163Abstract: The invention is directed to a method of detecting a malignancy or a pre-malignant lesion in breast or other tissue, or a pathologic condition, by detecting the presence of single-chain or two-chain forms of matriptase in the tissue. The invention is further directed to a method of treating malignancies, which have the phenotype of matriptase production by administering a tumor formation inhibiting effective amount of concentrate of Bowman-Birk inhibitor (BBIC), or other matriptase inhibitor. The invention also is directed to nucleic acids encoding a matriptase protein or fragments thereof, and their use for structure elucidation and modeling to identify other inhibitors of matriptase, as well as to methods of identifying matriptase modulating agents, including activators and inhibitors.Type: GrantFiled: February 29, 2008Date of Patent: June 14, 2011Assignee: Georgetown University School of MedicineInventors: Robert B. Dickson, Chen-Yong Lin, Michael Johnson, Shaomeng Wang, Istvan Enyedy
-
Publication number: 20080248566Abstract: The invention is directed to a method of detecting a malignancy or a pre-malignant lesion in breast or other tissue, or a pathologic condition, by detecting the presence of single-chain or two-chain forms of matriptase in the tissue. The invention is further directed to a method of treating malignancies, which have the phenotype of matriptase production by administering a tumor formation inhibiting effective amount of concentrate of Bowman-Birk inhibitor (BBIC), or other matriptase inhibitor. The invention also is directed to nucleic acids encoding a matriptase protein or fragments thereof, and their use for structure elucidation and modeling to identify other inhibitors of matriptase, as well as to methods of identifying matriptase modulating agents, including activators and inhibitors.Type: ApplicationFiled: February 29, 2008Publication date: October 9, 2008Applicant: Georgetown University School of MedicineInventors: Robert B. Dickson, Chen-Yong Lin, Michael Johnson, Shaomeng Wang, Istvan Enyedy
-
Patent number: 7355015Abstract: The invention is directed to a method of detecting a malignancy or a pre-malignant lesion in breast or other tissue, or a pathologic condition, by detecting the presence of single-chain or two-chain forms of matriptase in the tissue. The invention is further directed to a method of treating malignancies, which have the phenotype of matriptase production by administering a tumor formation inhibiting effective amount of concentrate of Bowman-Birk inhibitor (BBIC), or other matriptase inhibitor. The invention also is directed to nucleic acids encoding a matriptase protein or fragments thereof, and their use for structure elucidation and modeling to identify other inhibitors of matriptase, as well as to methods of identifying matriptase modulating agents, including activators and inhibitors.Type: GrantFiled: March 10, 2000Date of Patent: April 8, 2008Assignee: Georgetown University School of MedicineInventors: Robert B. Dickson, Chen-Yong Lin, Michael Johnson, Shaomeng Wang, Istvan Enyedy
-
Patent number: 7037776Abstract: A method of fabricating a DRAM cell, comprising the following steps. A substrate is provided. An isolation structure is formed within the substrate. The substrate is patterned to form nodes adjacent the isolation structure. Doped regions are formed with the substrate adjacent the nodes. A gate dielectric layer is formed over the patterned substrate, lining the nodes. A conductive layer is formed over the gate dielectric layer, filling the nodes. The conductive layer is patterned to form: a top electrode capacitor within the nodes; and respective word lines over the substrate adjacent the top electrode capacitor; each word line having exposed side walls. Source/drain regions are formed adjacent the word lines.Type: GrantFiled: December 19, 2002Date of Patent: May 2, 2006Assignee: Taiwan Semiconductor Manufacturing Co., Ltd.Inventors: Jenn-Ming Huang, Chen-Yong Lin